Latest news with #IBS-C
Business Upturn
06-05-2025
- Business
- Business Upturn
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025 EBX-102-02 was well tolerated and demonstrated clinically meaningful improvements across multiple symptom domains in IBS-C patients Ph2b trial in IBS-C initiating in H2 2025 to confirm efficacy Glasgow, Scotland – 6 May 2025. EnteroBiotix Limited ('EnteroBiotix'), a biopharmaceutical company developing best-in-class therapies for gut health, today presented positive data from its TrIuMPH Phase 2a trial evaluating EBX-102-02, the Company's next-generation oral full-spectrum microbiome product, in patients with irritable bowel syndrome with constipation (IBS-C) at Digestive Disease Week® (DDW) 2025, taking place 3–6 May in San Diego, USA. The multicentre, randomised, double-blind, placebo-controlled TrIuMPH trial evaluated the safety, tolerability, and efficacy of EBX-102-02 in 122 patients with moderate to severe irritable bowel syndrome with constipation (IBS-C) or diarrhoea (IBS-D). Participants were randomised 2:1 to receive 8 capsules of EBX-102-02 on Day 1 and Day 7 or matched placebo, with follow-up through Week 6. Data presented at DDW focused on the IBS-C cohort; results from the IBS-D cohort are expected in Q2 2025. EBX-102-02 was well tolerated, with adverse events primarily mild, self-limiting, and gastrointestinal in nature. Patients receiving EBX-102-02 showed clinically meaningful improvements and favourable trends compared to placebo across multiple endpoints, including the IBS Symptom Severity Score (IBS-SSS), abdominal pain, stool consistency, straining severity, average weekly complete bowel movements, PAC-SYM, and IBS Quality of Life (IBS-QoL). Improvements were observed as early as Week 1 and were sustained through follow-up. Shotgun metagenomic sequencing demonstrated robust strain engraftment, with the microbiome profiles of treated patients shifting toward the composition of the EBX-102-02 product. Highlights from the TrIuMPH trial presented at DDW 2025 included: IBS-SSS: Patients receiving EBX-102-02 showed greater improvement in IBS-SSS than placebo across all measured timepoints, with mean reductions of 78 points compared to 53 in the placebo group by Week 7. Patients receiving EBX-102-02 showed greater improvement in IBS-SSS than placebo across all measured timepoints, with mean reductions of 78 points compared to 53 in the placebo group by Week 7. Abdominal Pain: Mean abdominal pain severity dropped by 14.1 points in the EBX-102-02 group compared to 9.3 in the placebo group by Week 7. There was an improvement in the number of days with reported abdominal pain, with a 2.0 day reduction in the EBX-102-02 compared to 1.1 day reduction in the placebo group at Week 7. Mean abdominal pain severity dropped by 14.1 points in the EBX-102-02 group compared to 9.3 in the placebo group by Week 7. There was an improvement in the number of days with reported abdominal pain, with a 2.0 day reduction in the EBX-102-02 compared to 1.1 day reduction in the placebo group at Week 7. Bristol Stool Form: The weekly average number of stools classified as hard (BSFS 1 or 2) fell from 69% to 30% in the EBX-102-02 group compared to a decrease from 67% to 54% with placebo by Week 3. The weekly average number of stools classified as hard (BSFS 1 or 2) fell from 69% to 30% in the EBX-102-02 group compared to a decrease from 67% to 54% with placebo by Week 3. Complete Bowel Movement Frequency : Patients receiving EBX-102-02 experienced greater improvement in complete bowel movements than those on placebo, with an average increase of over one bowel movement per week in 4 out of 6 follow-up weeks, compared to 2 out of 6 weeks in the placebo group. : Patients receiving EBX-102-02 experienced greater improvement in complete bowel movements than those on placebo, with an average increase of over one bowel movement per week in 4 out of 6 follow-up weeks, compared to 2 out of 6 weeks in the placebo group. Microbiome Shift Toward Product Composition: Faecal microbiota profiles in the EBX-102-02 group shifted toward the composition of the drug product and this effect persisted through Week 7. Dr. James McIlroy MBChB, CEO of EnteroBiotix, commented: 'These positive data in EBX-102-02 for IBS-C represent a significant milestone for EnteroBiotix and for the broader field of microbiome-based therapeutics. EBX-102-02 was well tolerated and demonstrated consistent, clinically meaningful improvements across multiple IBS symptoms and measurements of quality of life. The observed microbial engraftment reinforces our confidence our full-spectrum approach. We look forward to advancing EBX-102-02 into a Ph2b trial later this year and were pleased to discuss these data with our Scientific Advisory Board during the Conference.' About EnteroBiotix EnteroBiotix is a clinical-stage biotechnology company developing microbiome-based therapeutics for irritable bowel syndrome (IBS) and other gastrointestinal and hepatic indications. Using its proprietary platform technology, EnteroBiotix creates next-generation therapies with differentiated characteristics designed to restore and enhance gut microbiome function. The company has established independent control over the supply chain for its drug formulations, with MHRA licensed manufacturing capabilities, and a donor programme called Number2®. About EBX-102-02 EBX-102-02 is a next-generation, full-spectrum microbiome therapeutic composed of a high-diversity consortium of gut-derived microbes. Manufactured using the Company's proprietary AMPLA™ technology, EBX-102-02 has a robust stability profile and is formulated as an off-white, odourless powder encapsulated into oral capsules. It is designed to deliver rapid, well-tolerated, and effective symptom relief for diseases associated with gut microbiome dysfunction, including irritable bowel syndrome (IBS). Media contacts EnteroBiotixDr James McIlroy, CEO [email protected]
Yahoo
30-04-2025
- Business
- Yahoo
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
BOSTON, April 30, 2025--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs. Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland. We routinely post information that may be important to investors on our website at In addition, follow us on X and on LinkedIn. View source version on Contacts Company contact: Greg Martinigmartini@ Investors: Precision AQ (formerly Stern Investor Relations)Stephanie Sign in to access your portfolio
Business Wire
30-04-2025
- Business
- Business Wire
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7 th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS ® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs. Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland. We routinely post information that may be important to investors on our website at In addition, follow us on X and on LinkedIn.
Associated Press
30-04-2025
- Business
- Associated Press
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
BOSTON--(BUSINESS WIRE)--Apr 30, 2025-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7 th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS ® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs. Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland. We routinely post information that may be important to investors on our website at In addition, follow us on X and on LinkedIn. View source version on CONTACT: Company contact: Greg Martini [email protected]: Precision AQ (formerly Stern Investor Relations) Stephanie Ascher [email protected] KEYWORD: UNITED STATES NORTH AMERICA NEW YORK MASSACHUSETTS INDUSTRY KEYWORD: HEALTH MANAGED CARE RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY SOURCE: Ironwood Pharmaceuticals, Inc. Copyright Business Wire 2025. PUB: 04/30/2025 04:25 PM/DISC: 04/30/2025 04:24 PM
